clinical trial · NCT06056570
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Urica Therapeutics Inc.·phase2·completed·n = 20
GoutHyperuricemiadontinuraddotinurad + allopurinolallopurinol
brief summary
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to assess the additive PD effects on serum uric acid and urinary urate excretion in U.S. patients with gout and hyperuricemia
started
Oct 4, 2023
primary completion
Jun 27, 2024
completion
Jul 9, 2024
last updated
Jan 28, 2025
official title
A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients with Gout and Hyperuricemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol